Professional Documents
Culture Documents
Company joins the National Colorectal Cancer Roundtable to meet goal by 2018.
Poway, CA, March 21, 2017 --(PR.com)-- Alfa Scientific Designs, Inc., (ALFA), a leader in the
development and manufacturing of rapid immunoassay point-of-care tests, has partnered with the
National Colorectal Cancer Roundtable (NCCRT) to support efforts to increase the number of people
screened for colorectal cancer and substantially reduce colorectal cancer as a major public health
problem.
We are proud to join forces with more than 500 local and national organizations to help to increase
colorectal cancer (CRC) screening rates by supporting the 80% by 2018 initiative," said Dr. Chai
Bunygidj, PhD., COO & General Manager. Our rapid, point-of-care immunochemical fecal occult blood
(iFOB) test for CRC pre-screening is widely available not only to clinicians and hospitals, but everyone
because it can be purchased over-the-counter for easy at-home use.
Colon cancer is the nation's second-leading cause of cancer-related deaths; however it is one of only a
few cancers that can be prevented. Colon cancer screening helps save lives by detecting polyps early so
they can be removed before they become cancerous. Early detection through screening is invaluable and
continues to play a pivotal role in the lives of more than 1 million colorectal cancer survivors across the
nation.
Alfa Scientific Designs, Inc., is one of the first companies to offer an over-the-counter (OTC) Fecal
Occult Blood test (FOBT) for colon cancer pre-screening. In just few short, simple steps, an FOBT can be
performed in the privacy and comfort of the patient's home. With unprecedented speed and 99.5%
accuracy, results are seen as quickly as one minute.
Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
Alfa Scientific Designs, Inc.
Jeanette Christian - Marketing Communications
858-413-1276
Contact via Email
www.alfascientific.com
News Image:
Page 2/2
PR.com Press Release Distribution Terms of Use